Fig. 4: MCL-1 secures survival of lung cancer derived cell lines.
From: MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
a MCL-1 copy number variation, MCL-1 mRNA, and MCL-1 protein levels in the cell lines used for this study. Data in the bottom panel are presented as mean ± SEM. b Relative viability of the indicated cell lines after 72 h treatment with 5 µM S63945, as determined by CellTiter-Glo®. Results were normalised to vehicle treated (control) cells. c Simple linear regression between MCL-1 protein levels (AU, arbitrary units) and cell viability after S63945 treatment (dashed lines 95% confidence interval; R2 = 0.5441, p = 0.0233). d Relative viability of the cell lines after 72 h treatment with 3 µM ABT-737, as determined by CellTiter-Glo®. Results were normalised to vehicle treated (control) cells (one-way ANOVA p = 4.540E−6, F(2,26) = 20.49). e Relative viability of the indicated cell lines 24 h after induction of the expression of the different BIMS variants, as determined by FACS analysis. Percentage of viable untreated cells was assigned as 100% (one-way ANOVA: NCI-H358: p = 2.317E-12, F(3,24) = 75.45; NCI-H1975: p = 1.354E−13, F(3,24) = 97.82; NCI-H2170: p = 3.334E–12, F(3,20) = 70.48). In figure are reported the p value from the post-hoc analysis with Bonferroni correction. Data in panel (b, d, and e) are presented as box plots, where the centre line represents the median value, the limits represent the 25th and 75th percentile, and the whiskers represent the minimum and maximum value of the distribution, excluding outliers defined using the IQR rule. Each cell line was assayed at least in three independent experiments.
